University of Oklahoma Confirms Cell Proliferation Suppression Effect of Novel Pancreatic Cancer Target Molecule Candidates Discovered by FRONTEO's AI

FRONTEO announced that novel target molecule candidates for pancreatic cancer, identified by its AI drug discovery service 'Drug Discovery AI Factory (DDAIF)', have been confirmed to suppress cancer cell proliferation in a joint study with Professor Naoko Takebe at the University of Oklahoma. In vitro experiments showed growth suppression across various pancreatic cancer cell lines. The candidates are highly novel, with little to no previous literature reporting their association with pancreatic cancer. The two parties plan to advance to animal testing to accelerate clinical development for this disease with extremely high unmet medical needs.